Connective tissue growth factor (CTGF) is a putative proto-oncogene and plays a crucial role in endothelial cell migration and tumor angiogenesis. CTGF is highly upregulated in proliferating endothelial cells and glioblastoma cells. In this investigation, we examined whether knockdown of CTGF at the mRNA level and treatment with temozolomide (TMZ) could inhibit cell invasion, angiogenesis, and growth of human glioblastoma U251MG and LN18 cells in vivo. The cells were stably transfected with a plasmid vector carrying the human CTGF siRNA cDNA and then treated with 10 μM TMZ for 48 h. Semiquantitative PCR, Western blotting, and immunohistochemical staining demonstrated 80% downregulation of CTGF both at mRNA and protein levels after stable transfection. Matrigel invasion, cell migration from spheroids, and cell proliferation studies demonstrated significant inhibition of cell invasion, migration, and proliferation, respectively, of both cell lines after downregulation of CTGF and treatment with TMZ. In vitro and in vivo angiogenesis assays demonstrated inhibition of network formation of endothelial cells and neovascularization under the dorsal skin of nude mice, respectively, after knockdown of CTGF and treatment with TMZ. Both subcutaneous and intracerebral tumorigenesis in nude mice was markedly reduced in CTGF downregulated cells after TMZ treatment. Mechanistic studies demonstrated significant reduction of PCNA, VEGF, c-Myc, CDK2, CDK4, and cyclin D1 and upregulation of the cell cycle inhibitors p21Waf1 and p27Kip1. Flow cytometric analysis showed cell cycle arrest at G2/M phase in both cell lines after CTGF knockdown and TMZ treatment. Taken together, our study indicates that the CTGF knockdown and TMZ treatment effectively prevents cell invasion, migration, angiogenesis, and growth of glioblastomas in vivo. Therefore, CTGF knockdown during TMZ treatment offers a novel and potential therapeutic strategy for controlling the growth of glioblastomas. This investigation was supported in part by the R01 grants (CA-91460 and NS-57811) from the National Institutes of Health (Bethesda, MD).
Introduction
Glioblastomas are the most common and very heterogenous form of malignant brain tumor in adults that causes significant mortality annually. The prognosis of patients with glioblastoma is extremely poor despite multimodal treatments including surgery, chemotherapy, and radiotherapy. The exact etiology of glioblastoma is unknown, but mostly related to genetic factors. Glioblastomas occur due to multiple genetic alterations, which result in the activation of oncogenes and/or the inactivation of tumor suppressor genes. A major challenge in patients with glioblastomas is the propensity of the tumor cells to invade rapidly deep into the surrounding tissues. The current standard of care includes maximal safe surgical resection, followed by a combination of radiation and chemotherapy. Highly invasive glioblastoma cells escape surgical removal and, because of their increased resistance to apoptosis, they are relatively resistant to radiation and chemotherapy. Limitations of current therapeutic regimens warrant development of explicit treatment strategies targeting the specific molecular aberrations that underlie the pathogenesis of glioblastoma. Development of appropriate combination therapeutic strategies involving gene therapy and chemotherapy would help to alleviate the aggressive behavior of this fatal tumor and thereby an effective treatment.
Connective tissue growth factor (CTGF or CCN2) is a cysteine-rich, matrix-associated, heparinbinding, secreted protein that belongs to the CCN family. CTGF is a putative proto-oncogene and plays a crucial role in endothelial cell migration and tumor angiogenesis. CTGF is remarkably upregulated in proliferating endothelial cells and glioblastoma cells. There is growing body of evidence that CTGF regulates cancer cell migration, invasion, angiogenesis, and tumor progression. CTGF mRNA levels were elevated in primary glioblastomas, and high levels of CTGF mRNA were directly correlated with advanced tumor stage and less differentiation and patient survival. Forced expression of CTGF in glioblastoma multiforme (GBM) cells accelerated their growth in liquid culture and soft agar, stimulated cells migration in Boyden chamber and significantly increased their ability to form large, vascularized tumors in nude mice. Appropriate strategies to downregulate CTGF would be beneficial to improve the efficacy of current therapeutic agents and/or for the effective treatment of glioblastomas.
Temozolomide (TMZ) is an alkylating agent , which is currently in use for the treatment of GBM. TMZ alkylates/methylates DNA, which often occurs at the N-7 or O-6 positions of guanine residues and damages DNA and triggers tumor cell death. However, certain tumor cells are able to repair TMZ mediated DNA damage by expressing O-6-alkylguanine-DNA alkyltransferase (MGMT) or O-6-alkylguanine-DNA alkyltransferase (AGT or AGAT). Epigenetic silencing of the MGMT gene by promoter methylation compromises DNA repair and has been associated with longer survival in glioblastoma patients who receive TMZ. The TMZ induced autophagy of glioblastoma cells is associated with the upregulation of several molecules including CTGF. Overexpression of CTGF caused the U343 GBM cells to survive for longer than 40 days in serumfree medium and resist anti-tumor drugs including tumor necrosis factor (TNF), TNF-related apoptosis-inducing ligand (TRAIL), and TMZ. Knockdown of Galectin-1 expression in Hs683 orthotopic xenografts by siRNA administration caused endoplasmic reticulum stress and enhanced the therapeutic effects of TMZ.
Small interfering RNAs (siRNAs) can silence the expression of a particular gene by its complementary binding and cleavage of mRNA, which results in significant disruption of translation of that particular gene. We have demonstrated effective knockdown of several upregulated genes in glioblastoma cell lines as well as in glioblastoma orthotopic xenograft models. The present study was aimed to knockdown the upregulated CTGF and simultaneous treatment with TMZ in two highly invasive human glioblastoma cell lines, U251MG and LN18, and to examine whether such a combination could inhibit cell invasion, angiogenesis, and tumor growth in subcutaneous and orthotopic xenograft models. 
